The Prescription Drug Affordability Board will meet on August 3 at 9:30am to consider several items.

The Prescription Drug Affordability Board consists of five members and three alternates appointed by the governor. The Board was created by SB 844 during the 2021 regular session to protect Oregon residents, state and local governments, commercial health plans, health care providers, pharmacies, and other stakeholders in the health care system in Oregon from the high costs of prescription drugs.​ The board includes Akil Patterson, Chair, Shelley Bailey, Vice Chair, Daniel Hartung, and Richard Bruno. Persons wishing to participate should register in advance.

To sign up for public comment, email your request to Prescription Drug Affordability Board at pdab@dcbs.oregon.gov 24 hours before the meeting. Include your name, organization, and the related agenda item. Written comments need to be provided 72 hours prior to scheduled meeting. Any written comments after 72 hours will be included for board consideration at the next meeting. Send comments to pdab@dcbs.oregon.gov and include your name, organization, and the related agenda item.

Among the items to be considered is distinguishing between recommendations in Sections 5 and 7 in SB 844

SECTION 5. No later than December 31 of each year, the Prescription Drug Affordability Board shall report to the Health Care Cost Growth Target program established in ORS 442.386 and to the interim committees of the Legislative Assembly related to health, in the manner provided in ORS 192.245, the following information:
(1) Price trends for the list of prescription drugs provided to the board by the Department of Consumer and Business Services under section 2 (1) of this 2021 Act;
(2) The prescription drugs that were reviewed under section 2 of this 2021 Act; and
(3) Recommendations, if any, for legislative changes necessary to make prescription drug products more affordable in this state


SECTION 7. (1) The Prescription Drug Affordability Board shall study the entire prescription drug distribution and payment system in this state and polices adopted by other states and countries that are designed to lower the list price of prescription drugs including but not limited to the following options: (a) Establishing upper payment limits for all financial transactions in this state involving a drug and specifying the methodology used to determine the upper payment limit that does not undermine the viability of any part of the prescription drug supply chain;
(b) Using a reverse auction marketplace for the purchase of prescription drugs by state and local governments; and
(c) Implementing a bulk purchasing process for state and local governments to purchase prescription drugs.
(2) No later than December 31, 2022, the board shall complete the study described in subsection (1) of this section and report to the interim committees of the Legislative Assembly related to health in the manner provided in ORS 192.245:
(a) The board’s findings including findings for each option described in subsection (1) of this section; and
(b) Recommendations for policies to lower the list prices of prescription drugs sold in this state and for legislative changes necessary to implement the policies.

--Staff Reports

Post Date: 2022-07-27 07:07:07

Last Update: 2022-07-26 18:06:03